Company
Every published round Novartis International took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Novartis International has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Novartis International, as distinct from the investments it has made.
Companies Novartis International has backed that another company then bought. An exit for the holding, not a deal Novartis International did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Novartis International is recorded as having been acquired. | ||||
Companies Novartis International acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Spinifex | Acquisition | 29 Jun 2015 | $267m | Startup Daily, AFR Technology |
| Spinifex Pharmaceuticals | Acquisition | 29 Jun 2015 | $200m+ | bionity.com, news-medical.net, PR Newswire |
Stories naming Novartis International. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UniSuper commits $75 million to Uniseed, the research commercialisation fund owned by four universities and CSIRO, its first venture investment; past portfolio sales to Schneider Electric, RTP Co and Novartis are recalled.
Chronic-pain drug developer Spinifex Pharmaceuticals has agreed to be bought by Novartis for US$200 million upfront plus undisclosed milestones, centred on its lead candidate EMA401.
Swiss pharmaceutical giant Novartis has agreed to acquire Australian drug developer Spinifex Pharma for $US200 million upfront, with up to $US500 million more in milestone payments.
Also Startup Daily